CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
Paclitaxel +2 moredrug
Likely dose
Paclitaxel 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00655850
NCT00655850Phase 2Completed

Pilot Phase II Study of Metronomic Chemotherapy in Combination With Avastin in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

University of Alabama at Birmingham·interventional·Posted Apr 10, 2008·Updated Jul 17, 2017

In Brief

A Phase 2 clinical trial evaluating Paclitaxel, Gemcitabine, and 1 other intervention for Non-Small Cell Lung Cancer. Completed, enrolled 39 participants across 1 site.

Detailed Summary

This study is being done to determine the overall progression-free survival (PFS) in patients with advanced or metastatic (Stage IIIB - pleural effusion/IV), non-squamous histology NSCLC treated with metronomic chemotherapy plus Avastin. Also, currently there are no defined markers that predict for clinical benefit to Avastin. Preliminary studies show that there are several observations that support the concept of metronomic chemotherapy with or without the combination of an anti-angiogenic agent. The metronomic chemotherapy with Avastin was shown to enhance the clinical endpoints of the study (response rate and progressive-free survival). Proof of metronomic scheduling requires the development of appropriate intermediate surrogate markers. Several markers will be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 10, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2015
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 18.2 years ago

Interventions

Paclitaxeldrug

* Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion: * Dexamethasone 20mg, intravenously (IV) * Diphenhydramine 50 mg IV * Ranitidine 50 mg IV * Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion. * The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15) Paclitaxel Dose Levels: * Dose Level 1 \_\_\_\_\_\_\_\_80 mg/m2/weekly * Dose Level -1 \_\_\_\_\_\_\_\_70 mg/m2/weekly

Gemcitabinedrug

Premedication * Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine. * Prior to receiving paclitaxel chemotherapy * Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion. * The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced. Gemcitabine Dose Levels: * Dose Level 2 \_\_\_\_\_\_\_\_300 mg/m2/weekly * Dose Level 1 \_\_\_\_\_\_\_\_200 mg/m2/weekly * Dose Level -1 \_\_\_\_\_\_\_\_150 mg/m2/weekly

Avastinbiological

* The dose of Avastin is 10 mg/kg IV every 2 weeks * It will be administered following the administration of chemotherapy * The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively. * It should not be administered or mixed with dextrose solutions.